Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its…
U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the…
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also…
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023 TEL AVIV, Israel–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and…
Complete Response Letter Received for AVT02 Biologics License Application TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and…
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals,…
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn’s Disease AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib, 45…
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship,…
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications AbbVie (NYSE: ABBV) announced today the intent to voluntarily withdraw, in the U.S., accelerated…
CoolSculpting® Elite Announces First Ever CoolMonth LAUNCHES THE COOLEST PROMOTION WITH A BUY 4, GET 4 DEAL AT PARTICIPATING PROVIDERS TO SUPPORT YOUR BODY CONTOURING JOURNEY IRVINE, Calif., April 3, 2023 /PRNewswire/…
Biogen Appoints Adam Keeney as Head of Corporate Development Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17…
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has…